Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.

Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.

Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or a human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.

Abstract: Disclosed is an external nasal splint which is adapted so that it may be placed across the bridge of the human nose, where it facilitates breathing without irritating the skin across the bridge of the nose. The splint contains a planar sheet of flexible material which has in its length-wise direction a central portion and two opposing end portions. The planar sheet is joined to an adhesive layer which also has in its length-wise direction a central portion and two opposing end portions. The central portion and the two opposing end portions of the planar sheet have an upper surface which is not adhesive to human skin. The two opposing end portions of the adhesive layer have a lower surface which is adhesive to human skin, so that the two opposing end portions are capable of affixing the external nasal splint to the human nose for a typical period of use, for instance six to twenty-four hours; and the central portion has a lower surface which is not adhesive to human skin.